We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

SYMBICORT® in the Treatment of COPD (SRP COPD)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00564499
First Posted: November 28, 2007
Last Update Posted: January 28, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
AstraZeneca
November 26, 2007
November 28, 2007
January 28, 2011
March 2006
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00564499 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
SYMBICORT® in the Treatment of COPD
A Scientific Research Program to Evaluate the Efficacy of SYMBICORT® 320/9μg in the Treatment of COPD in Real Life Environment by General Practitioners
A Scientific Research Program to evaluate the efficacy of SYMBICORT® 320/9μg in the treatment of COPD in real life environment by General Practitioners
Not Provided
Observational
Observational Model: Case-Crossover
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
patients
COPD
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
Not Provided
May 2007
Not Provided

Inclusion Criteria:

  • patients (m/f) with COPD (GOLD stadium III and IV)

Exclusion Criteria:

  • patients who recently quit smoking (<3months)
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
 
NCT00564499
SRP-RB-COPD-2005/1
No
Not Provided
Not Provided
Not Provided
AstraZeneca
Not Provided
Principal Investigator: E Louis, PR Université Libre de Liège
AstraZeneca
January 2011